Form 6-K DR REDDYS LABORATORIES For: Jul 11

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2016

Commission File Number 1-15182

 

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes   ¨            No  x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-            .

 

 

 

---

EXHIBITS

 

Exhibit Number		Description of Exhibits
99.1		Letter from National Securities Depository Limited Confirming Debit of Extinguished Equity Shares, dated June 22, 2016.
99.2		Notice to Stock Exchanges of Daily Reporting of Buyback and Extinguishment of Shares, dated June 24, 2016.
99.3		Notice to Stock Exchanges of Daily Reporting of Buyback and Extinguishment of Shares, dated June 27, 2016.
99.4		Notice to Stock Exchanges of Closure of Buyback of Equity Shares, dated June 28, 2016.
99.5		Post Buyback Public Advertisement for the Attention of the Equity Shareholders/Beneficial Owners of Equity Shares of Dr. Reddy’s Laboratories Limited, dated June 29, 2016
99.6		Letter from National Securities Depository Limited Confirming Debit of Extinguished Equity Shares, dated June 30, 2016.
99.7		Certificate of Extinguishment of Equity Shares bought back by Dr. Reddy’s Laboratories Limited in the month of June 2016, dated June 30, 2016.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

				DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: July 11, 2016				By:		/s/ Sandeep Poddar
						Name: Sandeep Poddar
						Title: Company Secretary

Exhibit 99.1

 

 

Ref: II/CA/COM/20939/2016		June 22, 2016

The Company Secretary

Dr. Reddys Laboratories Limited

8-2-337, Road No. 3

Banjara Hills

Hyderabad - 500034

Sub: Buy-back (open market purchase)

Dear Sir,

As per the corporate action(s) executed by your R&T Agent/Registry Division viz; Bigshare Services Pvt. Limited, Equity Shares were credited/debited to the account(s) in the NSDL system, details of which are given below:

 

ISIN		ISIN Description		D/C		Records		Quantity		Execution Date
INE089A01023		DR. REDDY`S LABORATORIES LIMITED EQ FV RS 5/-		Debit		1		1,674,213.000		22/Jun/2016

You may contact your R&T Agent/ Registry Division for further details in this regard.

Yours faithfully,

Nitin Ambure

Vice President

Digitally Signed By

Name: AMBURE NITIN

Date: 22/06/2016 15:05:54

Reason: Authentication

Location: NSDL, Mumbai

 

		4th Floor, ‘A’ Wing, Trade World, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, India Tel.: 91-92-2499 4200 | Fax: 91-22-2497 6351 | CIN-U74120MH2012PLC230380 | Email: [email protected] | Web: www.nsdl.co.in

Exhibit 99.2

 

		Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507   Tel: +9140 4900 2900 Fax: +9140 4900 2999 Email: [email protected] www.drreddys.com

June 24, 2016

 

BSE Limited Department of Corporate Services Listing Department P J Towers Dalal Street Mumbai - 400 001 Scrip Code: 500124		National Stock Exchange of India Limited Listing Department Exchange Plaza Plot no. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Code: DRREDDY

Dear Sir/Madam,

 

Sub:

Buyback of equity shares of Rs. 5/- each (“Share”) of Dr. Reddy’s Laboratories Limited (“Company”) at a maximum price of Rs. 3,500/- per share for a maximum amount of Rs. 15,69,41,71,500 (Rupees One Thousand Five Hundred Sixty Nine Crores Forty One Lacs Seventy One Thousand Five Hundred only) via the open market through stock exchanges (“Buyback”)

With reference to the captioned subject matter, the Company hereby submits the daily report pursuant to Regulation 15(i) of the SEBI (Buy Back of Securities) Regulations, 1998 regarding equity shares bought back on June 24, 2016:

 

Name of the Broker

Number of Equity Shares Bought Back on (24/06/2016)

Total shares bought back

Average Price of Acquisition (Rs.)

BSE

NSE

Kotak Securities Limited (A)

Nil

13,049

13,049

NSE: 3,114.59

Cumulative Equity Shares bought as on Yesterday (upto 23/06/2016) (B)

50,24,178

Less: Quantity Closed Out Today (C)

Nil

Quantity Closed Out as on Yesterday (D)

Nil

Total Quantity closed out (E=C+D)

Nil

Total Equity Shares bought back as on 24/06/2016 (A)+(B)–(E)

50,37,227

Please note that the total amount earmarked for Buyback by the Company is Rs. 15,69,41,71,500 (Rupees One Thousand Five Hundred Sixty Nine Crores Forty One Lacs Seventy One Thousand Five Hundred only) (excluding brokerage, transaction charges and taxes, if any).

Out of the above amount, the Company has utilized 99.18% i.e Rs. 15,56,61,89,408.28 (Rupees one thousand five hundred and fifty six crores sixty one lakhs eighty nine thousand and four hundred and eight and twenty eight paisa only) on cumulative basis for Buyback (excluding brokerage, transaction charges and taxes, if any) till date 24/06/2016.

For Dr. Reddy’s Laboratories Limited

 

/s/ Vikas Sabharwal

Vikas Sabharwal

Assistant Company Secretary

CC: New York Stock Exchange Inc. (Stock Code: RDY)

Exhibit 99.3

 

		Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507   Tel: +9140 4900 2900 Fax: +9140 4900 2999 Email: [email protected] www.drreddys.com

June 27, 2016

 

BSE Limited Department of Corporate Services Listing Department P J Towers Dalal Street Mumbai - 400 001 Scrip Code: 500124		National Stock Exchange of India Limited Listing Department Exchange Plaza Plot no. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Code: DRREDDY

Dear Sir/Madam,

 

Sub:

Buyback of equity shares of Rs. 5/- each (“Share”) of Dr. Reddy’s Laboratories Limited (“Company”) at a maximum price of Rs. 3,500/- per share for a maximum amount of Rs. 15,69,41,71,500 (Rupees One Thousand Five Hundred Sixty Nine Crores Forty One Lacs Seventy One Thousand Five Hundred only) via the open market through stock exchanges (“Buyback”)

With reference to the captioned subject matter, the Company hereby submits the daily report pursuant to Regulation 15(i) of the SEBI (Buy Back of Securities) Regulations, 1998 regarding equity shares bought back on June 27, 2016:

 

Name of the Broker

Number of Equity Shares Bought Back on (27/06/2016)

Total shares bought back

Average Price of Acquisition (Rs.)

BSE

NSE

Kotak Securities Limited (A)

Nil

40,277

40,277

NSE: 3,177.48

Cumulative Equity Shares bought as on Yesterday (upto 24/06/2016) (B)

50,37,227

Less: Quantity Closed Out Today (C)

Nil

Quantity Closed Out as on Yesterday (D)

Nil

Total Quantity closed out (E=C+D)

Nil

Total Equity Shares bought back as on 27/06/2016 (A)+(B)–(E)

50,77,504

Please note that the total amount earmarked for Buyback by the Company is Rs. 15,69,41,71,500 (Rupees One Thousand Five Hundred Sixty Nine Crores Forty One Lacs Seventy One Thousand Five Hundred only) (excluding brokerage, transaction charges and taxes, if any).

Out of the above amount, the Company has utilized 99.999% i.e Rs. 15,69,41,68,907.18 (Rupees one thousand five hundred and sixty nine crores forty one lakhs sixty eight thousand and nine hundred and seven and eighteen paisa only) on cumulative basis for Buyback (excluding brokerage, transaction charges and taxes, if any) till date 27/06/2016.

For Dr. Reddy’s Laboratories Limited

/s/ Sandeep Poddar

Sandeep Poddar

Company Secretary

CC: New York Stock Exchange Inc. (Stock Code: RDY)

Exhibit 99.4

 

		Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507   Tel: +9140 4900 2900 Fax: +9140 4900 2999 Email: [email protected] www.drreddys.com

June 28, 2016

 

BSE Limited Department of Corporate Services Listing Department P J Towers Dalal Street Mumbai - 400 001 Scrip Code: 500124		National Stock Exchange of India Limited Listing Department Exchange Plaza Plot no. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Code: DRREDDY

Dear Sir/Madam,

 

Sub:	Closure of Buyback of equity shares of Rs. 5/- each (“Equity Shares”) of Dr. Reddy’s Laboratories Limited (“Company”).

This is in reference to the above captioned subject, our intimation dated February 17, 2016 and the Public Announcement dated April 11, 2016, filed with you in respect of Buyback of equity shares of the Company at a price not exceeding Rs.3,500/- (Rupees three thousand five hundred only) per equity share (“Maximum Buyback Price”), upto an aggregate amount not exceeding Rs. 15,694,171,500 (Rupees One Thousand Five Hundred Sixty Nine Crores Forty One Lacs Seventy One Thousand Five Hundred only) (“Maximum Buyback Size”).

The Buyback was from all Shareholders of the Company (including persons who become shareholders, by cancelling American Depository Shares) held by them and receiving the underlying Equity Shares but excluding promoters and promoter group of the Company under the open market route in accordance with the provisions contained in SEBI (Buy Back of Securities) Regulations, 1998 (including any statutory modification(s), or re-enactment for the time being in force).

In this regard, we would like to inform you that the Company has bought back 5,077,504 equity shares at an average price of Rs.3,090.92 per share. The Company has thus deployed Rs. 15,694,168,907 (Rupees One Thousand Five Hundred Sixty Nine Crores Forty One Lacs Sixty Eight Thousand Nine Hundred and Seven only) (99.999%) against the Maximum Buyback Size.

The pre-Buyback and post-Buyback shareholding pattern, is also attached for your reference and information.

Consequently, the Company announces closure of its Buyback today i.e. June 28, 2016.

This is for your information and record.

For Dr. Reddy’s Laboratories Limited

/s/ Sandeep Poddar

Sandeep Poddar Company Secretary

Enc: As above

CC: New York Stock Exchange Inc. (Stock Code: RDY)

---

Pre-Buyback and post-Buyback shareholding pattern of the Company

 

Particulars		No. of Equity shares				% holding to total existing equity capital				No. of Equity shares								% holding to post Buyback equity capital*
		As on 31 March 2016								Post Completion of Buyback (As on 28 June 2016)
Promoters and/or persons who are in control			4,36,49,762				25.58				4,36,49,762								26.37
Public Shareholding															12,18,80,387				73.63
Indian Financial Institutions			45,87,435				2.69
Banks			2,42,636				0.14
Mutual Funds			54,45,931				3.19
Indian Public & Corporates			2,00,02,458				11.73
Foreign Institutional Investors			6,14,10,798				36.00
NRIs			20,85,783				1.22
Foreign Nationals			5,762				0.00
Foreign Companies			45,94,279				2.70
American Depository Shares (ADS)			2,85,82,809				16.75
TOTAL			17,06,07,653				100.00				16,55,30,149								100.00

 

*	The Company is in the process of extinguishing the balance 53,326 equity shares out of the total of 50,77,504 equity shares bought back. The post buyback share capital is provided assuming extinguishment of all shares bought back by the Company.

Exhibit 99.5

 

		DR. REDDY’S LABORATORIES LIMITED 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507; Tel.: +91 40 4900 2900; Fax: +91 40 4900 2999 Website: www.drreddys.com; e-mail: [email protected]

POST BUYBACK PUBLIC ADVERTISEMENT FOR THE ATTENTION OF THE EQUITY SHAREHOLDERS/BENEFICIAL OWNERS OF EQUITY SHARES OF DR. REDDY’S LABORATORIES LIMITED

Post Buyback Public Advertisement in accordance with the Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 (‘Buyback Regulations’) including any statutory modification(s), or re-enactment for the time being in force, regarding completion of the Buyback by Dr. Reddy’s Laboratories Limited (the ‘Company’) of its own equity shares from all of its Shareholders (including persons who become Shareholders, by cancelling American Depository Shares (ADS) held by them and receiving the underlying equity shares but excluding promoters and promoter group of the Company).

This Advertisement should be read in conjunction with the Public Announcement dated 11 April 2016 (‘Public Announcement’), issued in connection with the Buyback (as defined below). Unless specifically defined herein, capitalized terms and abbreviations used herein have the same meaning as ascribed to them in the Public Announcement.

 

1.	THE BUYBACK

 

1.1	The Post Buyback Public Advertisement (‘Advertisement’) is made in accordance with Sections 68, 69 and 70 of the Companies Act, 2013 (‘the Act’) and pursuant to Regulation 19(7) of the Buyback Regulations.

 

1.2	The Board of Directors of the Company (the ‘Board’) approved the proposal for buyback, at its meeting held on 17 February 2016. The Shareholders of the Company approved the proposal for the Buyback by the Company of its equity shares through postal ballot by a special resolution on 1 April 2016.

 

1.3

The Board in the aforementioned meeting, and the Shareholders by way of a special resolution on 1 April 2016, passed by postal ballot, in accordance with Article 61 of the Articles of Association of the Company and pursuant to the provisions of Sections 68, 69, 70 and other applicable provisions, if any, of the Act and Rules made thereunder and in compliance with the Buyback Regulations and, subject to such other approvals, permissions and sanctions as may be necessary, and subject to such conditions and modifications, if any, as may be prescribed or imposed by such regulatory authorities, while granting such approvals, permissions and sanctions, approved the Buyback by the Company of its fully paid up equity shares for an aggregate amount not exceeding Rs 15,69,41,71,500/- (Rupees one thousand five hundred sixty nine crores forty one lacs seventy one thousand five hundred only), (‘Maximum Buyback Size’), excluding transaction costs (‘Transaction Costs’) viz. brokerage, applicable taxes such as securities transaction tax, service tax, stamp duty, being 14.9% of the total paid up share capital and free reserves of the Company based on the audited financial statements of the Company as at 31 March 2015 (being the date of the then last audited financial statements of the Company), for a price not exceeding Rs. 3,500/- (Rupees three thousand five hundred only) per equity share (‘Maximum Buyback Price’) via the open market through Indian stock exchanges, from all Shareholders of the Company (including persons who become shareholders, by cancelling American Depository Shares (‘ADS’) held by them and receiving the underlying equity shares but excluding promoters and promoter group of the Company) under the Buyback Regulations and the Act (the ‘Buyback’).

---

1.3	The Buyback commenced on 18 April 2016 and closed on 28 June 2016. Till the date of closure of Buyback, the Company has utilized 100% of Maximum Buyback Size authorized for the Buyback (excluding Transaction Costs) with a balance of Rs. 2,593/-.

 

1.4	The total number of shares bought back under the Buyback are 50,77,504 equity shares.

 

2.	DETAILS OF THE BUYBACK

 

2.1

The Company bought back a total of 5,077,504 equity shares, utilizing a total of Rs. 15,69,41,68,907.18 (Rupees one thousand five hundred and sixty nine crores forty one lakhs sixty eight thousand and nine hundred and seven and eighteen paisa only) (excluding Transaction Costs) which represents 100% of the Maximum Buyback Size with a balance of Rs. 2,593/-. The price at which the equity shares were bought back was dependent on the price quoted on the BSE Limited (‘BSE’) and National Stock Exchange of India Limited (‘NSE’), together referred to as ‘Stock Exchanges’. The highest price at which the equity shares were bought back was Rs. 3,200 per equity share while the lowest price was Rs. 2,934.80 per equity share. The equity shares were bought back at an average price of Rs. 3,090.92 per equity share. These prices are based on the contract notes issued by the Company’s Broker (Kotak Securities Limited) and exclude transaction costs.

 

2.2.	The payout formalities have been completed as per settlement with the Stock Exchanges. The Company has extinguished 50,24,178 equity shares till date and is in the process of extinguishing the remaining 53,326 equity shares bought back.

 

2.3

As the buyback of equity shares was done from the open market through Stock Exchanges, the identity of shareholders from whom equity shares exceeding one percent of the total equity shares bought in the Buyback is not known, except for equity shares in physical segment for which the identity is known but none of them were exceeding one percent of the total equity shares bought in the Buyback.

 

3.	CAPITAL STRUCTURE AND SHAREHOLDING PATTERN

 

3.1	The pre-Buyback and post-Buyback capital structure of the Company is as follows:

 

Share Capital		As on the date of Public Announcement		Post Completion of Buyback (As on 28 June 2016)
Authorized		Rs. 1,20,00,00,000 (24,00,00,000 equity shares of Rs 5/- each)		Rs. 1,20,00,00,000 (24,00,00,000 equity shares of Rs 5/- each)
Issued		Rs. 85,30,39,265 (17,06,07,853 equity shares of Rs 5/- each fully paid up)		Rs. 82,76,51,745* (16,55,30,349 equity shares of Rs 5/- each fully paid up)
Subscribed and fully paid-up		Rs. 85,30,38,265 (17,06,07,653 equity shares of Rs 5/- each fully paid up)		Rs. 82,76,50,745* (16,55,30,149 equity shares of Rs 5/- each fully paid up)

 

*	The Company is in the process of extinguishing the balance 53,326 equity shares out of the total of 50,77,504 equity shares bought back. The post buyback share capital is provided assuming extinguishment of all shares bought back by the Company.

---

3.2	The pre-Buyback and post-Buyback shareholding pattern of the Company is as follows:

 

Particulars		No. of Equity shares				% holding to total existing equity capital				No. of Equity shares								% holding to post Buyback equity capital*
		As on 31 March 2016								Post Completion of Buyback (As on 28 June 2016)
Promoters and/or persons who are in control			4,36,49,762				25.58								4,36,49,762				26.37
Public Shareholding:
Indian Financial Institutions			45,87,435				2.69								12,18,80,387				73.63
Banks			2,42,636				0.14
Mutual Funds			54,45,931				3.19
Indian Public & Corporates			2,00,02,458				11.73
Foreign Institutional Investors			6,14,10,798				36.00
NRIs			20,85,783				1.22
Foreign Nationals			5,762				0.00
Foreign Companies			45,94,279				2.70
American Depository Shares (ADS)			2,85,82,809				16.75
TOTAL			17,06,07,653				100.00								16,55,30,149				100.00

 

*	The Company is in the process of extinguishing the balance 53,326 equity shares out of the total of 50,77,504 equity shares bought back. The post buyback share capital is provided assuming extinguishment of all shares bought back by the Company.

 

4.	MERCHANT BANKER TO THE BUYBACK

 

 

Name		:		Kotak Mahindra Capital Company Limited
Address		:		27 BKC, C 27, G Block, Bandra Kurla Complex,
				Bandra (E), Mumbai 400051
Phone		:		(022) – 43360128
Fax		:		(022) – 67132445
Contact Person		:		Mr. Ganesh Rane
Email		:		[email protected]

 

5.	For further details you may refer to the Company’s website – www.drreddys.com and websites of stock exchanges – www.bseindia.com and www.nseindia.com.

---

6.	DIRECTOR’S RESPONSIBILITY

The Board of Directors of the Company accepts responsibility for all the information contained in this Post Buyback Public Advertisement.

For and on behalf of the Board of Directors

of Dr. Reddy’s Laboratories Limited

 

G V Prasad		Kalpana Morparia		Sandeep Poddar
Co Chairman, MD & CEO		Independent Director		Company Secretary

Date: June 29, 2016

Exhibit 99.6

 

 

Ref: II/CA/COM/22224/2016		June 30, 2016

The Company Secretary

Dr. Reddys Laboratories Limited

8-2-337, Road No. 3

Banjara Hills

Hyderabad - 500034

Sub: Buy-back (open market purchase)

Dear Sir,

As per the corporate action(s) executed by your R&T Agent/Registry Division viz; Bigshare Services Pvt. Limited, Equity Shares were credited/debited to the account(s) in the NSDL system, details of which are given below:

 

ISIN		ISIN Description		D/C		Records		Quantity		Execution Date
INE089A01023		DR. REDDY`S LABORATORIES LIMITED EQ FV RS 5/-		Debit		1		53,326.000		30/Jun/2016

You may contact your R&T Agent/ Registry Division for further details in this regard.

Yours faithfully,

Rakesh Mehta

Assistant Vice President

Digitally Signed By

Name: MEHTA RAKESH MAHASUKHLAL

Date: 30/06/2016 13:15:19

Reason: Authentication

Location: NSDL, Mumbai

 

		4th Floor, ‘A’ Wing, Trade World, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, India Tel.: 91-92-2499 4200 | Fax: 91-22-2497 6351 | CIN-U74120MH2012PLC230380 | Email: [email protected] | Web: www.nsdl.co.in

Exhibit 99.7

 

		Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel: +9140 4900 2900 Fax: +9140 4900 2999 Email: [email protected] www.drreddys.com

June 30, 2016

Securities Exchange Board of India,

Plot No.C4-A, ‘G’ Block,

Bandra Kurla Complex,

Bandra (East),

Mumbai 400051

Dear Sir/Madam,

Sub.: Certificate of Extinguishment of Equity shares bought back by Dr. Reddy’s Laboratories Limited (‘Company’) in the month of June, 2016

This certificate is being issued in compliance with the requirements of Regulation 16(1) read with Regulation 12(3)(b) of the Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 and subsequent amendments thereto.

Pursuant to the Public Announcement (PA) published on April 12, 2016, the Company commenced the Buyback of equity shares of face value of Rs. 5/- each fully paid up (Equity shares), from the open market through Stock Exchange from April 18, 2016.

The Company has bought back 3,920,186 equity shares during the period from May 25, 2016 to June 27, 2016 (both days inclusive).

 

1)	The shares extinguished in Demat form in the month of June, 2016 are as under:

 

Name of Depository Participant and DP Id No.

Company’s Client Id No.

Date of Extinguishment

No. of Equity shares extinguished

Kotak Mahindra Bank Limited IN302814

12714023

June 8, 2016

752,214

June 20, 2016

1,440,395

June 22, 2016

1,674,213

June 30, 2016

53,326

Total

3,920,148

 

2)	The shares extinguished in Physical form in the month of June, 2016: 2 (Two) on June 14, 2016 and 36 (Thirty six) on June 21, 2016.

 

3)	Total shares bought back and extinguished in Demat and Physical form: 3,920,186.

 

4)	Reconciliation of Share Capital of the Company (Pre and Post extinguishment):

Reconciliation of Share Capital of the Company (Pre and Post extinguishment) for the month of June 30 2016

 

Sl. No.		Particulars		No. of Shares		Share Capital (in Rs.)
1.		Paid up Share capital as on June 1, 2016		169,450,335		847,251,675
2.		Shares extinguished during the month of June, 2016		3,920,186		19,600,930
Paid up share capital (Post Extinguishment) as on June 30, 2016				165,530,149		827,650,745

---

This is to certify that the above equity shares of the Company, being in demat form and physical form were extinguished in compliance with the provisions of Regulations 12(2) and 16(3) of the Buyback Regulations.

This is for your information.

With regards

For Bigshare Services Private Limited

(Registrar & Share Transfer Agent)

 

/s/ T. P. Raju

T. P. Raju

Authorised Signatory

For Dr. Reddy’s Laboratories Limited

 

/s/ G V Prasad				/s/ Kalpana Morparia
G V Prasad				Kalpana Morparia
Co-Chairman, MD & CEO				Independent Director

For B S R & Co. LLP

Chartered Accountants

Firm Registration No. 101248W/W-100022

 

/s/ Supreet Sachdev

Supreet Sachdev

Partner

Membership No. 205385

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY) PT Lowered to INR5,700 at Goldman Sachs
• Ensurge Micropower ASA - Grant of Incentive Subscription Rights
• The First Bancshares, Inc. Reports Results for First Quarter ended March 31, 2024